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Abstract
Merkel cell carcinoma (MCC) is an aggressive
dermal tumour of neuroendocrine origin. MCC is a rare
tumour and all information pertaining to its behaviour,
therapy and prognosis is based on retrospective reports. The
two potentially curative treatment modalities are surgery
and radiotherapy. It is a rare, highly malignant primary skin
tumour, originally called "trabecular carcinoma" of the skin.
MCC poses a challenge to the clinician because of its rarity
and poor prognosis. The optimal therapy is customised and
tailored for each individual patient with the appropriate use
of operative resection and radiation therapy. This review
covers reports from several authors regarding the rationale
of using postoperative radiotherapy to the primary tumour
and regional lymphatics. Although MCC is classified as a
type of neuroendocrine carcinoma, it is less likely to be
controlled by systemic chemotherapy. Management of
primary lesion with clinically localised disease is wide
excision with margin of at least 2 cm whenever possible.
MCC is a radiosensitive tumour, adjuvant radiotherapy has
been advocated in order to control local as well as regional
disease Radiation induced toxicity should be considered and
discussed with the patient. Adjuvant radiation to the nodal
bed after complete lymphadenectomy in patients with
metastatic disease is generally not recommended.
Introduction
Merkel cell carcinoma (MCC) is an aggressive
dermal tumour of neuroendocrine origin. It is a rare, highly
malignant primary skin tumour, originally called "trabecular
carcinoma" of the skin. MCC poses a challenge to the
clinician because of its rarity and poor prognosis.1 It was
first described by Toker in 1972.2 He had observed that the
tumour originates from the neuroendocrine cells of the basal
epidermis of the skin. Merkel described the cell of the origin
as epidermal, non-dendritic, non-kerotinocytic cell that he
referred to as a tactile cell.3 Electron microscopy and
immunocytochemical studies are often required for accurate
diagnosis.
Clinical Features: Although this carcinoma is
usually found in elderly individuals, it can occur in young
patients as well. Median age at presentation is
approximately 67 years. The vast majority of patients
affected by MCC are white. It has strong male
predominance. Mostly MCC, occur on areas of the body
exposed to sunlight.4 Common sites of the tumour are head
and neck (47-50%), extremities (40%) and trunk (8%).
The aetiology of MCC is not known. Sun exposure
is considered as one of the risk factors as ultra violet
exposure induced C to T mutation was found in some MMC
cell lines.5 The occurrence of MCC has also been reported
in HIV infected patients together with other malignancies.
Recent reports have shown an increased incidence in
immunosuppressed transplant patients, in rheumatoid
arthritis and in B cell malignancies. 
The natural history of MCC shares many common
features with melanoma like melanoma MCC is also a
cutaneous malignancy of same embryonic origin. These two
malignancies also show similar clinical features and
behaviour e.g an early spread to nodal sites, high local
recurrence rate and early metastasis.6
Yom et al7 suggested that the differential diagnosis
of Merkel cell carcinoma should be included in patients
presenting with mucosal lesions of head and neck,
especially if the tumor is sub-mucosal. MCC can also
involve the tongue. Mucosal MCC is aggressive, and there
is a high risk for local recurrence and regional and distant
metastasis.7
Diagnostic evaluation: Histologically the tumour
consists of sheets of small round blue cells, an appearance
that is similar to melanoma and metastatic small cell
carcinoma. Immunohistochemical stains may be used to
determine whether the primary tumour is indeed a primary
MCC of the skin or cutaneous metastases from a visceral
small cell carcinoma. MCC has immunohistochemical
features of both neuroendocrine and epithelial cells. It is
usually positive for cytokeratin, CK20 (unlike melanoma
and metastatic squamous cell carcinoma) and is usually
negative for S100 and thyroid transcription factor 1(TTF-1),
a newly described nuclear protein that appears to be specific
for small cell carcinoma of pulmonary origin.8
A report published in Anticancer Research in June
2006 has evaluated the role of cell cycle-regulatory
proteins(p53/p21/p27) in Merkel Cell Carcinoma's
pathogenesis and prognosis. Twenty-four primary MCC
specimens with corresponding clinical data were analysed
by immunohistochemistry for p21, p27 and p53 antibodies.
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The staining was evaluated semi-quantitatively and the
results were analysed. p53 was negative in 80% and p21 in
71% of the samples. Positive staining for p27 was evident in
92% of the samples. However, the expression of these
antibodies did not correlate with the outcome of the patient. 
The proportion of p53- and p21-negative samples
seems to indicate that correction processes after DNA
damage are not activated during MCC pathogenesis, a
supposition that is supported by the aggressive nature of this
tumour. It was concluded that the above mentioned three
cell cycle regulators cannot serve as prognostic markers for
survival.9
Under the microscope most of the MCC specimens
show a clear Grenz zone separating the epidermis from the
tumour.The immunohistochemistry of MCC exhibits
positive staining to neurofilament,cytokeratin,neuron
specific enolase and epithelial membrane antigen.10
Staging: Patient with MCC can be staged according
to the American Joint Committee on Cancer (AJCC) staging
system for skin cancer. Alternatively, a relatively simple
system was proposed by Yiengpruksawan et al.11 which can
be used for stage grouping:
StageI : patients with localized disease; those with
tumour of less than 2 cm are considered stage 1A, whereas
those with tumour of 2 cm or more are considered as stage
1B.
Stage II, with regional lymph node metastasis 
Stage III; with distant metastasis.
Yiengpruksawan and colleagues have reported that
at the time of first consultation 70% to 80% of patients with
MCC have stage I, 10% to30%have stage II and 15 to 4%
have stage III disease.11
Treatment: MCC is a rare tumour and all
information pertaining to its behaviour, therapy and
prognosis is based on retrospective reports. The two
potentially curative treatment modalities are surgery and
radiotherapy. The optimal therapy is individualised in any
given patient with the appropriate use of operative resection
and radiation therapy. Several authors reported that
postoperative radiotherapy to the primary tumour and
regional lymphatic significantly improves local control and
disease free survival,12 The mainstay of treatment is wide
local excision of tumour with reconstructive surgery.13
Management of primary lesion with clinically
localised disease is wide excision with a margin of at least
2 cm whenever possible. The excision should include the
skin and subcutaneous tissue. Resection of the underlying
fascia is also performed when the tumour is close to it.
Excision margins of less than 3cm are associated with high
incidence of local failures.11 Due to high incidence of nodal
metastasis, prophylactic lymphadenectomy is also
suggested in some reports, alternatively sentinel node
biopsy can be considered as an appropriate procedure in
clinically node negative patient. Approximately 25% of
patients are found to have metastatic disease in the sentinel
node biopsy. Early removal of microscopic disease detected
by this diagnostic approach may offer the patient a greater
opportunity for cure.14 It is often difficult or impossible to
excise MCC of the head and neck or distal extremity with a
wide margin. Adjuvant radiotherapy can be considered in
these cases. If the primary cancer is to be treated with
radiotherapy alone, the regional lymphatics may be
electively irradiated. Patient who present with fixed,
unresectable nodal metastasis are treated with preoperative
radiotherapy followed by salvage surgery of the primary site
with a possible nodal dissection.
MCC is a radiosensitive tumour, adjuvant
radiotherapy has been advocated in order to control local as
well as regional disease.12 Radiation induced toxicity
should be considered and discussed with the patient.
Adjuvant radiation to the nodal bed after complete
lymphadenectomy in patients with metastatic disease is
generally not recommented.  Regional recurrence is
uncommon after a complete lymphadenectomy is
performed in patients who had positive sentinel node
biopsy.14 On the other hand in patients with clinically
proven regional disease adjuvant radiation treatment
improves regional control.
There is no established dose response curve for the
MCC. It is quite likely that its response to radiation is
similar to that observed in squamous cell carcinoma.
Therefore, the dose fractionation schedule for patients with
negative surgical margin is of the order of 60 Gray in 30
fractions over 6 weeks or equivalent.15
Systemic chemotherapy is recommended in patients
with regional or systemic metastasis as a palliative measure.
It gives 50% to 60% palliative response rate which is found
to be more evident in patients with regional disease and less
for visceral metastases. The use of various
chemotherapeutic agents, both single and in combination,
are reported in the literature. Agents like
cyclophosphamide, doxorubicine, vincristine, etoposide,
cisplatin, carboplatin, octreotide and dacarbazine have
shown some palliative benefits.16 The option of systemic
chemotherapy should be offered to patients who present
with nodal or metastatic disease.17
A metanalysis concluded that surgery plus adjuvant
irradiation was associated with significantly lower rates of
local and regional recurrence of MCC than surgery alone.
Prospective investigation is needed to clarify the presence
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of a survival benefit from combination therapy.1
Swann and Yoon have done a review of MCC which
is published in the Seminars of Oncology in February 2007.
They have drawn some pertinent conclusions on the
prognosis and management of MCC. The prognosis of
MCC is variable. Natural history of localized disease is
indolent and these tumours are well controlled with local
excision alone. On the other side of spectrum , majority of
tumours behave aggressively and have a tendency for
locoregional recurrence and distant metastases. In locally
advanced and metastatic disease the option of systemic
chemotherapy with regimens similar to those which are
used in the treatment of  small cell carcinoma of the lung,
may be considered in adjuvant setting following surgery.18
MCC is characterized by a high incidence of local
and regional recurrence. Long term survival with low
incidence of recurrence is reported in patients with early
stage of tumour. Most recurrences occur in the first 24
months and frequent follow up during this period is
recommended. Patients who develop a local recurrence after
primary excision (regardless of site) should undergo re-
excision, if possible, and adjuvant radiotherapy should be
considered if not previously given. The long survival can be
achieved after the treatment of loco regional recurrence.
Voog and colleagues have reported that patients with loco-
regional relapse and distant metastasis had 2 year survival
rate of 35% and 17% respectively, versus 86% and 100%
respectively for those who do not have these two forms of
recurrences. The median overall survival after starting
chemotherapy was 9 months for patients with distant
metastasis and 24 months for patients with loco regional
disease.16 The role of immunotherapy is not fully defined.
Immunotherapeutic agents such as alpha- interferon or
intralesional application of tumour necrosis factor-alpha
were shown to have some effects in some patients.19,20
Sandel HD et al21 compared the clinical and
histopathological criteria including tumour size and depth
of invasion with clinical outcomes in MCC patients.
Disease-free survival rates were found to be 52%, 39%, and
9% at 1, 2, and 5 years, respectively. The average disease-
free interval was 18.4 months (range, 1-80 months). Overall
recurrence was found in 60.7% of patients with local
recurrence occurring in 18.1%, regional recurrence 40.9%,
and distant recurrence 47.8%. However, there was a trend
toward increased local and regional recurrence rates when
comparing size and depth and in specimens with positive
tumor margins.21
These outcomes are consistent with those reported in
recent literature and further characterize the unpredictable
nature of this disease. An aggressive approach should be
taken, including wide local excision with negative tumor
margins and lymph node dissection.
Ortin Parez et al22 have reported eight cases of MCC
who underwent sentinel node biopsy. All  sentinel nodes
were successfully harvested. Three patients (37.5%)
showed metastatic involvement and they were subjected to
regional lymphadenectomy.This report published in the
European Journal of Surgical Oncology  in February 2007
suggested that sentinel node biopsy appears to be a reliable
staging technique which can be considered in the surgical
management of MCC.22
A retrospective review was published in the Journal
of Surgical Oncology in March 2007. The review of 38
consecutive patients with surgically treated extremity MCC
was presented. Surgical techniques of Wide local excision
and  Mohs' surgery was compared. No difference in local
recurrence was found between the two procedures. A
reduced local recurrence rate was observed in patients who
were treated by adjuvant radiotherapy with a hazard ratio of
0.29 (95% Confidence Interval [0.10, 0.85]).It has no
impact on overall survival.This retrospective review further
supports the rationale of using adjuvant radiation therapy in
improving locoregional tumour control in MCC patients.23
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